Trending News: Swine Healthcare Market Growth Statistics to Make Multi-Billion Dollar Market during 2020-2027 – KSU ksusentinel.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ksusentinel.com Daily Mail and Mail on Sunday newspapers.
SeQuent announced launch of Citramox® LA in EU
Posted On: 2020-12-10 02:24:52 (Time Zone: Arizona, USA)
SeQuent Scientific Limited (SeQuent), announced launch of Citramox® LA 150 mg/ml Suspension Injection for Cattle and Pigs in 10 European countries, including the key markets of Western Europe. The product has recently received approval through its Spanish subsidiary Laboratorios Karizoo, S.A., and will be the first Long-Acting injectable to be offered by SeQuent in Europe.
This new approval for SeQuent builds on the recent approvals of Tulazzin® (Tulathromycin) and Halofusol® (Halofuginone) in Europe. All these approvals have been received within 12 months of filing, which reflects on SeQuent s growing strengths in introducing new products for the regulated markets.
Sequent Scientific rose 2.09% to Rs 173.45 after the company announced the launch of Citramox LA 150 mg/ml suspension injection for cattle and pigs in 10 European countries, including the key markets of Western Europe.
The product has recently received approval through its Spanish subsidiary Laboratorios Karizoo, S.A., and will be the first Long-Acting injectable to be offered by the company in Europe. This new approval for SeQuent Scientific builds on the recent approvals of Tulazzin (Tulathromycin) and Halofusol (Halofuginone) in Europe. All these approvals have been received within 12 months of filing.
Citramox is the first generic version of Vetrimoxin LA (Innovator: Ceva Animal Health Inc) to be approved and launched in Europe, which is an effective antibiotic indicated for the treatment of respiratory infections caused by Mannheimia haemolytica and Pasteurella multocida susceptible to amoxicillin in cattle and pigs.